Elevated Serum PCT in Septic Shock With Endotoxemia Is Associated With a Higher Mortality Rate

Barbara Adamik, PhD, Jakub Smiechowiec, MD, PhD, Dominika Jakubczyk, PhD, and Andrzej Kübler, MD, PhD

Abstract: To examine the effect of endotoxemia on the procalcitonin (PCT) serum levels and mortality rates of adult patients with septic shock diagnosed on the day of admission to the intensive care unit (ICU).

A retrospective observational study was performed over a 2-year period. Levels of PCT were compared for septic shock patients with and without endotoxemia on admission to the ICU. Endotoxemia was identified with an Endotoxin Activity Assay.

One hundred fifty-seven patients with septic shock were enrolled into the study. Group 1 consisted of patients with elevated endotoxin activity (EA) (n = 95, EA = 0.57 endotoxin activity unit [EU] [0.46–0.67]) and Group 2 consisted of patients with low EA (n = 62, EA = 0.27 EAU [0.17–0.36]). Acute Physiology And Chronic Health Evaluation II (APACHE II) score and SOFA score were similar in both groups (APACHE II = 23 [16–29] and 19 [16–25]; Sequential Organ Failure Assessment [SOFA] = 10 [7–13] and 11 [8–12] in Groups 1 and 2, respectively) (nonsignificant). The PCT level was 6 times higher in Group 1 than in Group 2 (19.6 ng/mL vs. 3.1 ng/mL, P < 0.001). There was a strong correlation between EA and serum PCT (P < 0.001, R = 0.5). The presence of endotoxemia on admission to the ICU was associated with an increased mortality rate: 52% in the group of patients with endotoxemia and 25% in the group without endotoxemia. EA in survivors was 0.39 EAU (0.26–0.57) and 0.53 EAU (0.4–0.61) in nonsurvivors (P = 0.004). The median PCT level in survivors was 6.7 ng/mL (2.3–28.0), compared with 16.7 ng/mL (5.3–31.0) in nonsurvivors (P = 0.04).

This observational study revealed that endotoxemia in patients with septic shock on admission to the ICU was frequently found and was associated with an elevated PCT level and a high mortality rate. Endotoxemia was a common occurrence in patients with septic shock, regardless of the infecting microorganism.

Abbreviations: ACCP/SCCM = American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference, APACHE II score = Acute Physiology And Chronic Health Evaluation II score, APTT = Activated partial thromboplastin time, CRPC = reactive protein, EA = Endotoxin activity, EAA = Endotoxin Activity Assay, EAU = Endotoxin activity unit, ICU = Intensive care unit, IL = interleukin, LPS = Lipopolysaccharide, n.s. = nonsignificant, PCT = Procalcitonin, PT = Prothrombin time, SOFA score = Sequential Organ Failure Assessment score, TLR = Toll-like receptor, TNF alpha = Tumor Necrosis Factor alpha, UTI = Urinary tract infection, WBC = White blood cell.

INTRODUCTION

Procalcitonin (PCT), a precursor of the hormone calcitonin, is synthesized physiologically by thyroid C cells. In normal human serum, the PCT level is low. Increased PCT levels were first reported by Assicot et al to be associated with various bacterial infections. In an animal model of sepsis, in which bacterial infection was induced by implanting Escherichia coli pellets, increased calcitonin mRNA expression as well as elevated PCT plasma level was observed in various tissues that are not usually viewed as being endocrine. Systemic PCT secretion is a component of the inflammatory response, and it is particularly evident in bacterial infections. Systemic changes are triggered by bacterial components, such as endotoxin, peptidoglycan, lipoteichoic acid, and lipoprotein; these components stimulate the production of many mediators of inflammation. There is evidence that gram-negative bacteria cause higher rises in PCT than gram-positive bacteria. The predictive value of PCT for clinical outcomes has been extensively studied in groups of critically ill patients and has yielded variable results. The damaging effect of PCT in the pathogenesis of sepsis has been reported based on animal studies. Administering PCT to septic animals had several toxic effects and greatly increased mortality. In contrast, an anti-inflammatory effect of PCT was reported in several studies. The capability of PCT to neutralize bacterial endotoxin and to reduce the tumor necrosis factor (TNF)-alpha level was demonstrated in a model of human peripheral blood mononuclear cells.

In this study, the effect of endotoxemia was evaluated on the PCT serum level and the mortality rate of patients with septic shock on the day of admission to the intensive care unit (ICU). An unresolved question is whether PCT is a harmful biomarker or a mediator that directly neutralizes bacterial lipopolysaccharide (LPS). Understanding the role of PCT in bacterial infection is crucial, because of the significant impact of endotoxemia on the PCT level and mortality in patients with septic shock, as was observed in this study.
SUBJECTS AND METHODS

Study Group

The study design was a single-center retrospective observational analysis of all adult patients with a diagnosis of septic shock admitted to the 25-bed mixed ICU in a 996-bed tertiary-care University Hospital from January 2012 to December 2013. The Ethics Committee of the Wroclaw Medical University approved the study protocol (KB-692/2014). The need for informed consent was waived due to the retrospective, observational nature of the study. Included in the study were adult patients with septic shock, according to the consensus definition of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (ACCP/SCCM)\(^\text{12}\) where the PCT level and endotoxin activity (EA) were measured within the first 24 h after admission to the ICU. All patients in the study received standard treatment for septic shock according to the Surviving Sepsis Campaign guidelines.\(^\text{13}\)

The baseline severity of the illness was quantified with the Acute Physiology and Chronic Health Evaluation II (APACHE II) score and the degree of organ dysfunction was assessed with a Sequential Organ Failure Assessment (SOFA) score on admission to the ICU. Demographic data, microbiology results, and routine parameters, such as white blood cell (WBC) count, C-reactive protein (CRP) level, creatinin and bilirubin level, and coagulation parameters (APTT, activated partial thromboplastin time; PT, prothrombin time) were also recorded.

PCT and Endotoxin Measurement

Serum concentrations of PCT were determined by an immunoluminometric assay (LUMI test PCT) (BRAHMS Diagnostica, Berlin, Germany) and the detection limit was 0.05 ng/mL. EA was measured in a whole blood sample drawn from an intravenous catheter to a tube with ethylenediaminetetraacetic acid (EDTA). Endotoxemia was identified with a Endotoxin Activity Assay (EAA, Spectral Diagnostics, Inc., Toronto, Canada), commercially available, CE, in vitro diagnostic (IVD) marked diagnostic test intended for measuring EA in clinical samples. This method is based on the detection of the respiratory burst activity generated in neutrophils. Oxygen radicals generated by primed neutrophils produce luminal chemiluminescence, and the signal is recorded with a luminometer (single tube luminometer Smart Line TL, Berthold Detection Systems GmbH, Pforzheim, Germany). The results are quantitative, expressed in endotoxin activity units (EAU) on a scale from 0 to 1, and they represent the mean value of duplicate analysis from each blood sample.

Outcomes and Statistical Analysis

Whole blood EAA and the PCT serum level were immediately measured in patients with septic shock on admission to the ICU. In accordance with the manufacturer’s information, endotoxia was defined as EA $\geq$ 0.4 EAU. Patients with septic shock on admission to the ICU were divided into 1 of 2 groups according to the EA results: Group 1 with elevated EA (EA $\geq$ 0.4 EAU) and Group 2 with low EA (EA < 0.4 EAU). The ICU mortality rate was recorded and the ICU length of stay was counted until discharge from the ICU or death. Only patients with septic shock diagnosed on the admission to the ICU were included. This was done in order to obtain the most homogenous group of ICU patients.

These data were analyzed with Statistica 10 (StatSoft, Inc., Tulsa, OK). Patients with missing data were excluded from the analysis. The distribution of the variables was not normal, based on a Shapiro–Wilks test. Therefore, statistical analysis of the data was performed using nonparametric techniques. Continuous variables are presented as medians with the 25th and 75th percentiles. The Mann–Whitney U test was used to compare differences between 2 independent groups. The relationship between the EA and other parameters was assessed with a Spearman rank correlation test. Categorical variables were analyzed using a Pearson $\chi^2$ test. Survival analysis of time to death was performed using the Kaplan–Meier curve and log-rank test. Statistical significance was determined as $P < 0.05$.

RESULTS

One hundred fifty-seven patients diagnosed with septic shock were enrolled into the study. All patients had their EA level measured on admission to the ICU and based on the value of the EA, patients were placed into Group 1 ($N = 95$; EA $= 0.57$ EAU [0.46–0.6]) or Group 2 ($N = 62$; EA $= 0.27$ EAU [0.17–0.36]). The severity of the clinical status as estimated by the APACHE II and SOFA scores was similar for both groups (APACHE II $= 23$ [16–29] and 19 [16–25]; SOFA $= 10$ [7–13] and 11 [8–12] in Groups 1 and 2, respectively) and no statistically significant difference was observed. The PCT level was 6 times higher in Group 1 than in Group 2 (19.6 ng/mL vs. 3.1 ng/mL, $P < 0.001$). The median serum creatinine value in patients with endotoxia was statistically greater ($P = 0.03$) than in patients without endotoxia and renal replacement therapy was instituted in 64% of patients in Group 1 and in 45% of patients in Group 2 ($P = 0.03$). There were no differences in the CRP, bilirubin, PLT count, WBC, and coagulation parameters between the study groups. The baseline characteristics of the study group are presented in Table 1.

PCT, Endotoxia, and Pathogen Detection

On admission to the ICU, serum PCT levels were higher than 0.5 ng/L in 95% of patients with septic shock; in 18% of patients $<2$ ng/mL, in 33% $\geq$ 2 to $<10$ ng/mL, and in 49% PCT $\geq$ 10. A higher level of serum PCT was associated with a significant decrease in the survival rate ($P = 0.05$) (Table 2). Endotoxemia, defined as EA $\geq$ 0.4 EAU, was present in 49% of patients ($P < 0.001$, $R = 0.5$). There was a strong correlation between EA and serum PCT ($P < 0.001$).

Pathogen Detection

In patients with endotoxia, a gram-negative pathogen was identified as the primary source of infection leading to septic shock in 68% of patients, a gram-positive in 20%, fungi in 3%, viral in 4%, and unknown in 5%. In patients without endotoxia, the distribution of pathogens was significantly different ($P = 0.002$): in 45% of patients a gram-negative pathogen was identified, a gram-positive in 34%, fungi in 6%, *Mycoplasma pneumonia* in 3%, viral in 2%, and unknown in 9%. The distribution of identified pathogens in both groups is shown in Figure 1. Bacteremia was detected more often in the group with endotoxia, compared to the group without endotoxia (26 [27%] vs. 8 [13%]; $P = 0.01$).

Survival Analysis

The ICU mortality of the whole study group of patients with septic shock was 41%. The Kaplan–Meier survival analysis of time to death showed that there was statistical significance between groups with and without endotoxia.
The presence of endotoxemia on admission to the ICU was associated with an increased mortality rate: 52% in the group with endotoxemia and 25% in the group without endotoxemia. Median EA in survivors was 0.39 EAU (0.26–0.57) and in nonsurvivors was 0.53 EAU (0.4–0.61) \((P=0.004)\). Median PCT level in survivors was 6.7 ng/mL (2.3–28.0), compared to 16.7 ng/mL (5.3–31.0) in nonsurvivors \((P=0.04)\).

**DISCUSSION**

The study revealed that endotoxemia in patients with septic shock on admission to the ICU was frequently found and was associated with an elevated PCT level. The mortality rate was 2 times higher in patients with increased EA.

Endotoxin, an LPS present in the outer cell membrane of gram-negative bacteria, is considered to be the principal mediator involved in the development of septic shock. LPS can be recognized by the toll-like receptor 4 (TLR4), a transmembrane receptor expressed in different immune cells, such as neutrophils, monocytes, macrophages, and dendritic cells.\(^{14}\) On activation, these cells produce inflammatory mediators, eg, the TNF and interleukins (IL-1\(\beta\), IL-6, IL-8, IL-10), which leads to the induction of a variety of inflammatory processes and may contribute to the development of major organ failure in the course of sepsis.\(^{15,16}\) Previous research indicates that endotoxemia is common in populations of ICU patients on the day of admission. In an MEDIC study, in a heterogeneous population of ICU patients, 57% had elevated EA.\(^{17}\) In another study, in which EA in a population of ICU

**TABLE 1. Demographic and Baseline Characteristics of Patients With Septic Shock**

| Variables                    | Endotoxemia (+) (N = 95) | Endotoxemia (−) (N = 62) | P  |
|------------------------------|---------------------------|---------------------------|----|
| Age, y                       | 66 (57–75)                | 63 (55–76)                | 0.44|
| Male, %                      | 64                        | 52                        |     |
| APACHE II score              | 23 (16–29)                | 19 (16–25)                | 0.10|
| SOFA score                   | 10 (7–13)                 | 11 (8–12)                 | 0.85|
| Diagnosis on admission, N    |                           |                           | 0.83|
| Peritonitis                  | 54                        | 53                        |     |
| Pneumonia                    | 24                        | 25                        |     |
| UTI                          | 10                        | 7                         |     |
| Skin and soft tissue infection | 12                       | 15                        |     |
| Endotoxin activity, EAU      | 0.57 (0.46–0.67)          | 0.27 (0.17–0.36)          | <0.001|
| Procalcitonin, ng/mL         | 19.6 (6.7–38.0)           | 3.1 (1.8–13.6)            | <0.001|
| WBC, 10⁹/μL                  | 15.7 (10.0–23.3)          | 16.4 (10.5–27.0)          | 0.47|
| CRP, mg/L                    | 180 (117–273)             | 179 (121–228)             | 0.48|
| Creatinine, mg/dL            | 1.82 (1.10–3.00)          | 1.3 (0.9–2.0)             | 0.03|
| Bilirubin, mg/dL             | 1.2 (0.7–2.5)             | 1.4 (0.7–2.1)             | 0.84|
| Platelets, 10⁹/μL            | 148 (83–252)              | 189 (72–296)              | 0.68|
| APTT, s                      | 46 (39–58)                | 43 (37–55)                | 0.20|
| PT, %                        | 78 (64–88)                | 77 (70–85)                | 0.79|
| ICU length of stay, d        | 12 (6–30)                 | 14 (8–29)                 | 0.93|
| ICU mortality, %             | 52                        | 25                        | 0.004|

Data are presented as medians with the 25th and 75th percentiles. \(P\) values illustrate comparisons between septic shock patients with and without endotoxemia. APACHE II = Acute Physiology and Chronic Health Evaluation II; APTT = activated partial thromboplastin time; CRP = C-reactive protein; EAU = endotoxin activity units; ICU = intensive care unit; PT = prothrombin time; SOFA = Sequential Organ Failure Assessment; UTI = urinary tract infection; WBC = white blood cell count.

**TABLE 2. Distribution of Serum Procalcitonin Levels (PCT) in 3 Reference Ranges in Survivors (N = 64) and Nonsurvivors (N = 93) \((P=0.05; \text{Pearson } \chi^2)\)**

| Procalcitonin Levels (PCT) | Survivors, % | Nonsurvivors, % |
|---------------------------|--------------|-----------------|
| PCT < 2 ng/mL             | 70           | 30              |
| PCT >2 to <10 ng/mL       | 68           | 32              |
| PCT >10 ng/mL             | 49           | 51              |

PCT = procalcitonin.
surgical patients was analyzed, the baseline EA level was elevated in 34% of patients. Our data add to the existing research on the prevalence of endotoxemia in patients diagnosed with septic shock; the majority of studied patients had an elevated EA level on admission to the ICU. Mortality in the group with septic shock and endotoxemia was 2 times higher than in patients without endotoxemia. Endotoxin is a powerful inducer of the inflammatory cytokine production, an activator of the inducible nitric oxide synthase, the complement system, and coagulation processes. All of these can contribute to the development of a systemic inflammatory reaction and could account for the observed higher mortality rate in the studied population. The effect on mortality rates of endotoxemia detected in different study groups on admission to the ICU has been described before. In a Yaguchi study performed on a heterogeneous population of ICU patients, the highest mortality rate was reported in patients with endotoxemia, with EA > 0.6 EAU. In our study, the Kaplan–Meier survival analysis revealed a significantly higher mortality rate in patients with endotoxemia, when EA > 0.4 EAU.

Endotoxemia in septic shock could be a manifestation of an exogenous infection or a result of LPS translocation. In this study in patients with endotoxemia, a gram-negative pathogen as the primary source of infection in septic shock was detected in the majority of patients; however, some patients with an infection other than gram-negative also had elevated EA. Endotoxemia in these patients could be the result of the translocation of gram-negative bacteria or LPS alone through the damaged intestinal wall to normally sterile tissues. Regional hypoperfusion and ischemia of the intestinal mucosa are factors that can promote translocation in septic shock. These data are consistent with that of previously reported studies. Yaguchi et al observed a low rate of gram-negative organisms in patients with sepsis and a low level of EA; this rate increased significantly to 70% in patients with elevated EA. The serum elevation of PCT recorded in the majority of patients with septic shock in our study might suggest that there had been previous stimulation of the inflammatory cytokine cascade and indicate a dependency of the PCT level on the release of the inflammatory mediators. It has been previously demonstrated that the administration of PCT alone does not initiate inflammatory cytokine release, either in healthy or septic animals, which suggests that PCT is a secondary mediator that requires other mediators to initiate production. In fact, it was observed that an injection of a pro-inflammatory cytokine—TNF-alpha—was associated with as high as a 25-fold increase in the PCT level 12h after TNF-alpha stimulation. Structural studies revealed that there are 2 LPS binding sequences present in the PCT molecule and PCT might directly bind to a lipid A in the LPS molecule and participate in endotoxin clearance. Matera et al examined the effect of PCT on the release of cytokines by human peripheral blood mononuclear cells and demonstrated that PCT neutralized LPS molecules and significantly decreased LPS reactivity in vitro. The decrease in the LPS level had an effect on cytokine production. A subsequent reduction in TNF-alpha, IL-10, and the mononuclear cell target chemokine (MCP-1) in LPS-stimulated cells was observed after incubation with PCT. In our study, the PCT level was high in patients with an elevated EA at the onset of septic shock. Considering the results of in vitro studies, it is possible that, at least in part, PCT in patients with septic shock and endotoxemia was produced and released to bind to and neutralize endotoxins circulating in the blood. It should be also noted that serum creatinine was significantly higher in the group with endotoxemia. Endotoxin induces cellular damage and is considered to be one of the factors behind the development of acute renal failure during sepsis. An induction of significant pro-apoptotic mechanisms by LPS in various renal cell types, including tubule cells and glomerular endothelial cells, has been observed and can effect renal function by decreasing the number of cells in the organ or inhibiting communication between cells. This potential pro-apoptotic mechanism leading to renal injury in sepsis can explain the finding in our study that the requirement for renal replacement therapy was higher in the group with endotoxemia. Admittedly, the observational and retrospective nature of this study was a limitation, and only patients with septic shock diagnosed on the admission to the ICU were included. This was done in order to obtain the most homogenous group of ICU patients.

CONCLUSIONS
The following are the conclusions of this study.

1. This study shows that endotoxemia is common in patients with septic shock.
2. Elevated EA can be detected in critically ill patients regardless of the infecting microorganism.
3. Endotoxemia is accompanied by a high PCT level in septic shock. A strong correlation was observed between EA and serum PCT (P < 0.001, R = 0.5).
4. The elevation of PCT level is associated with an increased mortality of patients with septic shock.
5. Endotoxemia is associated with an increased ICU mortality in patients with septic shock.

ACKNOWLEDGMENTS
The authors would like to thank Lukasz Strozecki, MSc, for the involvement in performing statistical analysis.

REFERENCES
1. Snider RH Jr, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med. 1997;45:552–560.
1. Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet*. 1993;341:515–518.

2. Müller B, White JC, Nylén ES, et al. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. *J Clin Endocrinol Metab*. 2001;86:396–404.

3. Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. *Chest*. 2010;138:121–129.

4. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. *Am J Respir Crit Care Med*. 2001;164:396–402.

5. Charles PE, Ladoire S, Aho S, et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either gram negative or gram positive bacteria. *BMC Infect Dis*. 2008;8:38.

6. Monneret G, Pachot A, Laroche B, et al. Procalcitonin and calcitonin gene related peptide decrease LPS-induced TNF production by human peripheral blood mononuclear cells. *BMC Microbiol*. 2012;12:68.

7. Becker KL, Snider R, Nylén ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. *Br J Pharmacol*. 2009;159:253–264.

8. Nylen ES, Whang KT, Snider RH Jr et al. Mortality is increased by procalcitonin and decreased by an antisera reactive to procalcitonin in experimental sepsis. *Crit Care Med*. 1998;26:1001–1006.

9. Matra G, Quirino A, Giancotti A, et al. Procalcitonin neutralizes bacterial LPS and reduces LPS-induced cytokine release in human peripheral blood mononuclear cells. *BMC Microbiol*. 2012;12:68.

10. Monneret G, Arpin M, Venet F, et al. Calcitonin gene related peptide and N-procalcitonin modulate CD11b upregulation in peripheral blood mononuclear cells. *Intensive Care Med*. 2003;29:923–928.

11. Monneret G, Pachot A, Laroche B, et al. Procalcitonin and calcitonin gene related peptide decrease LPS-induced TNF production by human circulating blood cells. *Cytokine*. 2000;6:762–764.

12. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med*. 1992;20:864–874.

13. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. *Crit Care Med*. 2008;36:296–327.

14. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell*. 2006;124:783–801.

15. van Deventer SJ, Böller HR, ten Cate JW, et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. *Blood*. 1990;76:2520–2526.

16. Cunningham PN, Dyanov HM, Park P, et al. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. *J Immunol*. 2002;168:5817–5823.

17. Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. *J Infect Dis*. 2004;190:527–534.

18. Valenza F, Fagnani L, Coppola S, et al. Prevalence of endotoxemia after surgery and its association with ICU length of stay. *Crit Care*. 2009;13:R102.

19. Opal SM, Scannlon PJ, Vincent JL, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. *J Infect Dis*. 1999;180:1584–1589.

20. Yaguchi A, Yuzawa J, Klein DJ, et al. Combining intermediate levels of the Endotoxin Activity Assay (EAA) with other biomarkers in the assessment of patients with sepsis: results of an observational study. *Crit Care*. 2012;16:R88.

21. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. *JAMA*. 2009;301:2445–2452.

22. Akira S, Takeda K. Functions of toll-like receptors: lessons from KO mice. *C R Biol*. 2004;327:581–589.

23. Tavares E, Maldonado R, Ojeda ML, et al. Circulating inflammatory mediators during start of fever in differential diagnosis of gram-negative and gram-positive infections in leukopenic rats. *Clin Diagn Lab Immunol*. 2005;12:1085–1093.

24. Whang KT, Vath SD, Becker KL, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. *Shock*. 2000;14:73–78.

25. Japelj B, Pristovsek P, Majerle A, et al. Structural origin of endotoxin neutralization and antimicrobial activity of a lactoferrin-based peptide. *J Biol Chem*. 2005;280:16955–16961.

26. Bhattacharjya S. De novo designed lipopolysaccharide binding peptides: structure based development of antendotox and antimicrobial drugs. *Curr Med Chem*. 2010;17:3080–3093.

27. Cunningham PN, Wang Y, Guo R, et al. Role of toll-like receptor 4 in endotoxin induced acute renal failure. *J Immunol*. 2004;172:2629–2635.

28. Ueda N, Kaushal GP, Shah SV. Apoptotic mechanisms in acute renal failure. *Am J Med*. 2000;108:403–415.

29. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. *Nat Rev Immunol*. 2006;6:813–822.